Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
is
under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date Breda, the Netherlands Jun. 16, 2021 argenx (Euronext & Nasdaq: ARGX), today announced that
The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Efgartigimod is currently under review with the U.S. Food and Drug Administration (FDA) for the treatment of gMG with a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2021, and if approved, would be the first-and-only approved FcRn antagonist.
Trial Results of New Drug for Generalized Myasthenia Gravis Published in Lancet Neurology miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
email article
More patients with myasthenia gravis who were treated with the investigational agent efgartigimod achieved a sustained improvement in a scale of activities of daily living compared with patients who were given placebo, a researcher reported.
Of patients with generalized myasthenia gravis and anti-acetylcholine receptor antibody (AChR-Ab) positivity in a phase III study, 67.7% receiving efgartigimod achieved at least a 2-point improvement in their Myasthenia Gravis-Activities of Daily Living (MG-ADL) score after the first cycle of treatment, compared with 29.7% of those receiving placebo (
P
Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
Full results from the Vivacity-MG study to be presented for the first time during an oral presentation
News provided by
Share this article
Share this article
TITUSVILLE, N.J., April 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the full results from the Phase 2 Vivacity-MG study of the investigational compound, nipocalimab (M281), in generalized myasthenia gravis (gMG)–a chronic, autoimmune neuromuscular disease. The data will be featured as part of an oral presentation at the American Academy of Neurology (AAN) Virtual Meeting taking place April 17-22, 2021.